Last updated: July 31, 2026
Nordette-21 is a combined oral contraceptive containing levonorgestrel 0.15 mg and ethinyl estradiol 0.03 mg in a 21-tablet regimen. It is an established hormonal contraceptive, not an investigational drug. No active clinical-development program, new molecular-entity trial program, or meaningful product-specific trial pipeline is associated with Nordette-21. Its commercial outlook depends on generic levonorgestrel/ethinyl estradiol supply, reimbursement, contraception policy, and brand availability rather than clinical-trial results.
The product’s original brand value has largely transferred to generic manufacturers. Patent-based exclusivity is not the principal barrier to market entry. The key commercial issues are regulatory listing, manufacturing scale, pharmacy access, pricing, and competition from other combined oral contraceptives and long-acting reversible contraceptives.
What is Nordette-21 and how does it work?
Nordette-21 is a monophasic combined oral contraceptive. Each active tablet contains:
| Attribute |
Nordette-21 |
| Progestin |
Levonorgestrel |
| Estrogen |
Ethinyl estradiol |
| Strength |
0.15 mg levonorgestrel / 0.03 mg ethinyl estradiol |
| Pack design |
21 active tablets |
| Administration |
One tablet daily for 21 consecutive days, followed by a tablet-free interval |
| Therapeutic class |
Combined hormonal contraceptive |
| Primary use |
Prevention of pregnancy |
Levonorgestrel suppresses ovulation through hypothalamic-pituitary-ovarian effects and increases cervical-mucus viscosity. Ethinyl estradiol supports ovulation suppression and stabilizes the endometrium. The FDA labeling for levonorgestrel/ethinyl estradiol oral contraceptives identifies pregnancy prevention as the principal indication.[1]
Nordette-21 differs from 28-day packs mainly in packaging and dosing presentation. A 21-day pack contains active tablets only, while a 28-day pack usually contains 21 active tablets plus seven inert or reminder tablets. The active hormonal formulation is often the same.
What clinical trials support Nordette-21?
Nordette-21 does not have a current clinical-trial program comparable to a new drug or reformulated contraceptive. Its clinical support comes from historical studies of combined oral contraceptives and postmarketing safety data for levonorgestrel/ethinyl estradiol products.
Clinical-trial status
| Clinical category |
Nordette-21 status |
| Phase 1 development |
No current product-specific program |
| Phase 2 development |
No current product-specific program |
| Phase 3 development |
No current product-specific program |
| FDA approval pathway |
Established drug approval and generic-equivalence pathways |
| Pivotal efficacy development |
Historical combined-oral-contraceptive evidence |
| Postmarketing surveillance |
Ongoing class-level safety monitoring |
| Biosimilar development |
Not applicable |
ClinicalTrials.gov may contain studies involving levonorgestrel, ethinyl estradiol, oral contraception, bleeding patterns, adherence, emergency contraception, or comparative contraceptive methods. Those studies should not automatically be attributed to Nordette-21. A trial involving the same active ingredients may use a different manufacturer, dose, pack design, or indication.
The relevant clinical evidence base evaluates contraceptive effectiveness, cycle control, adverse events, thromboembolic risk, blood-pressure effects, discontinuation, and adherence. Current FDA labeling warns about arterial and venous thrombotic events, particularly among individuals who smoke, have hypertension, or have other cardiovascular risk factors.[1]
What is the FDA regulatory status of Nordette-21?
Nordette-21 is regulated as a combined oral contraceptive containing established active ingredients. In the United States, equivalent products containing levonorgestrel and ethinyl estradiol have been marketed through abbreviated new drug applications and other established regulatory pathways.
The FDA’s regulatory treatment is product-specific. A manufacturer must establish pharmaceutical equivalence, bioequivalence where required, manufacturing compliance, labeling compliance, and quality control. The existence of an approved levonorgestrel/ethinyl estradiol product does not authorize every manufacturer to market the same formulation without its own approval.
FDA-related commercial considerations
- The active ingredients have long-established regulatory histories.
- Generic entry does not require a new efficacy program equivalent to an innovator contraceptive launch.
- Approved labels contain contraindications, warnings, dosing instructions, and patient information.
- Manufacturers remain responsible for current Good Manufacturing Practice compliance.
- Product availability can change because of discontinuation, manufacturing interruptions, recalls, or supply allocation.
The FDA labeling for representative levonorgestrel/ethinyl estradiol products identifies contraindications including a history of thrombotic disorders, certain migraine conditions, uncontrolled hypertension, significant liver disease, and breast cancer, subject to the specific product label.[1]
What patents protect Nordette-21?
No meaningful active patent estate is publicly associated with the original Nordette-21 brand that would block ordinary generic manufacture of the underlying formulation. The active ingredients are old, and the basic combination of levonorgestrel and ethinyl estradiol has long been available from multiple manufacturers.
Patent and exclusivity assessment
| Protection category |
Assessment |
| Active-ingredient composition patent |
No commercially relevant current barrier expected |
| Basic combination patent |
Historical protection has expired |
| 21-day pack configuration |
Generally weak or nonexclusive |
| Conventional tablet formulation |
Multiple generic alternatives limit enforcement value |
| Method-of-use patent |
No current Nordette-21-specific exclusivity identified |
| Manufacturing patent |
Potentially relevant only to a particular supplier or process |
| Regulatory exclusivity |
No new-product exclusivity expected |
| Biosimilar exclusivity |
Not applicable |
The Orange Book is the relevant FDA publication for approved drug products and listed patent information. Patent listings must be assessed at the specific product and application level. A generic levonorgestrel/ethinyl estradiol product can have different listed patents, labeling, or application status from another manufacturer’s product.[2]
For a conventional oral contraceptive, formulation or manufacturing patents would need a defensible claim scope and commercial relevance. A patent covering a particular excipient system, dissolution profile, packaging format, or manufacturing process may not prevent competitors from selling a therapeutically equivalent product using a different process or formulation.
When did Nordette-21 lose exclusivity?
The practical exclusivity period for the underlying Nordette-21 formulation ended long before the current generic market. Levonorgestrel and ethinyl estradiol are established contraceptive ingredients with extensive generic competition.
The relevant commercial conclusion is that Nordette-21 is post-exclusivity. Current market access is determined by approved generic applications, procurement contracts, distributor decisions, and pharmacy substitution rather than by remaining brand exclusivity.
No patent-expiration date should be treated as a current launch barrier without confirming a specific patent number, claim scope, jurisdiction, and listed product. For the conventional Nordette-21 formulation, no such active barrier is central to the market outlook.
Are there Paragraph IV challenges involving Nordette-21?
Paragraph IV litigation is not a central current risk for the conventional Nordette-21 product. Paragraph IV certifications typically arise when a generic applicant challenges patents listed in the FDA Orange Book for a branded reference product.
Because the underlying formulation is mature and generic versions have been available, the commercial importance of a new Paragraph IV filing would depend on the specific reference-listed drug, patent listing, and applicant. A certification against a patent covering a different package, indication, dosage regimen, or formulation would not necessarily affect ordinary 21-tablet levonorgestrel/ethinyl estradiol products.
Litigation risk
| Risk area |
Current assessment |
| Paragraph IV challenge to basic Nordette-21 formulation |
Low |
| Patent-infringement risk for standard generic tablets |
Low |
| Labeling litigation |
Possible, but product-specific |
| Product-liability litigation |
Ongoing class-level risk for combined hormonal contraceptives |
| Manufacturing and quality disputes |
Moderate operational risk |
| Supply and recall exposure |
Manufacturer-specific |
The most relevant legal exposure is product liability and safety litigation involving thromboembolic events, failure to warn, or alleged manufacturing defects. Those matters generally concern the broader combined-hormonal-contraceptive class and the applicable manufacturer’s labeling, not a single Nordette-21 patent estate.
What is the market for Nordette-21 and its generic equivalents?
Nordette-21 competes in a mature, price-sensitive oral-contraceptive market. Its closest competitors include other levonorgestrel/ethinyl estradiol products, norethindrone/ethinyl estradiol products, norgestimate/ethinyl estradiol products, drospirenone/ethinyl estradiol products, progestin-only pills, transdermal systems, vaginal rings, injectable contraceptives, intrauterine systems, and contraceptive implants.
Competitive comparison
| Product category |
Main commercial advantage |
Main limitation versus Nordette-21 |
| Generic levonorgestrel/ethinyl estradiol |
Low price and broad familiarity |
Limited differentiation |
| Norethindrone/ethinyl estradiol |
Established prescribing base |
Different tolerability profile |
| Drospirenone/ethinyl estradiol |
Differentiated progestin profile |
Higher price and additional safety considerations |
| Progestin-only pill |
Useful when estrogen is unsuitable |
More demanding dosing requirements for some products |
| Vaginal ring |
Less frequent administration |
Device acceptance and access |
| Intrauterine system |
Long duration and high effectiveness |
Procedure required |
| Contraceptive implant |
Long duration and low adherence burden |
Insertion and removal procedure |
Nordette-21’s commercial strengths are low manufacturing complexity, established physician familiarity, and generic substitution. Its weaknesses are limited brand differentiation, low average selling prices, lack of patent protection, and competition from longer-acting contraceptive methods.
What formulations are protected by Nordette-21 patents?
The conventional 21-tablet formulation has limited standalone protection. The following product characteristics are generally insufficient by themselves to create durable exclusivity:
- A 21-day active-tablet regimen
- Standard oral tablets
- Levonorgestrel at 0.15 mg
- Ethinyl estradiol at 0.03 mg
- Conventional blister packaging
- Standard monthly dispensing
Potentially protectable elements could include a novel controlled-release system, a distinct delivery platform, a specific low-dose formulation, an unusual excipient combination, or a manufacturing process. Those elements would relate to a particular product and patent owner rather than automatically to the Nordette-21 brand.
Does Nordette-21 have biosimilar risk?
Biosimilar risk is not applicable. Nordette-21 is a small-molecule oral tablet, not a biologic. Competitive substitution occurs through generic-drug approval pathways rather than biosimilar approval under the Public Health Service Act.
The relevant competitors are abbreviated new drug application holders and other suppliers of therapeutically equivalent levonorgestrel/ethinyl estradiol products. Pharmacy substitution depends on state law, payer policy, formulary placement, and the specific product’s FDA therapeutic-equivalence rating.
What licensing deals affect Nordette-21?
No major current licensing transaction is central to the commercial outlook for conventional Nordette-21. The original brand and historical manufacturing rights may have changed through corporate acquisitions, divestitures, or product-portfolio transfers, but those transactions do not create new exclusivity for the generic formulation.
Current commercial relationships are more likely to involve:
- Contract manufacturing
- Private-label supply
- Wholesale distribution
- Pharmacy benefit management
- Government procurement
- Regional marketing authorization holders
These arrangements can affect supply and pricing without changing the underlying patent position.
What is the market projection for Nordette-21?
Nordette-21 is best projected as a mature generic-category product rather than as a branded growth asset.
Base-case projection
The base case is stable to declining unit demand for the original brand, with continued availability of generic equivalents. Revenue growth is unlikely unless a supplier gains distribution, secures a procurement contract, or addresses a shortage affecting competing products.
Upside scenario
An upside scenario would require one or more of the following:
- Temporary shortages among competing manufacturers
- Improved pharmacy or payer access
- A private-label contract
- Expansion into an underpenetrated geographic market
- A supply agreement with a government or institutional buyer
- Brand relaunch under a differentiated packaging or adherence proposition
Downside scenario
The downside case includes:
- Brand discontinuation
- Persistent low pricing
- Manufacturing interruptions
- Product recalls
- Reduced oral-contraceptive use in favor of long-acting methods
- Payer exclusion
- Supplier consolidation
Commercial projection by metric
| Metric |
Outlook |
| Brand revenue |
Low and structurally pressured |
| Generic unit demand |
Stable to moderately declining |
| Generic price |
Low, with periodic supply-driven volatility |
| Patent-driven margin expansion |
Unlikely |
| Clinical-development value |
Minimal |
| Manufacturing value |
Moderate if supply reliability is strong |
| Licensing value |
Limited for the basic formulation |
| Geographic expansion value |
Higher in markets with limited contraceptive access |
Public sources do not support a reliable product-specific revenue forecast for Nordette-21 because sales are generally reported within broader contraceptive or generic-drug categories. A defensible valuation should use manufacturer-level prescription volume, tender data, product availability, net pricing, and geographic market share rather than brand-level global assumptions.
How strong is the Nordette-21 patent estate?
The patent estate is weak as a current commercial defense. The product’s strategic value lies in manufacturing efficiency and distribution, not exclusivity.
| Patent-strength factor |
Rating |
| Composition-of-matter protection |
Weak or expired |
| Formulation differentiation |
Weak for standard tablets |
| Method-of-use protection |
Weak |
| Regulatory exclusivity |
None expected |
| Generic substitution defense |
Weak |
| Manufacturing know-how |
Potentially moderate |
| Supply-chain differentiation |
Potentially moderate |
| Litigation leverage |
Low |
A supplier seeking to defend pricing would need operational differentiation, such as reliable supply, lower cost of goods, regulatory execution, or channel access. Patent litigation is unlikely to provide a durable commercial moat for the standard formulation.
What generic launch risks exist for Nordette-21?
Generic launch risk is low from a patent perspective and moderate from an operational perspective.
The principal risks are:
- Regulatory deficiencies in an abbreviated application.
- Failure to demonstrate required bioequivalence or quality attributes.
- Manufacturing inspection findings.
- Supply interruption involving active pharmaceutical ingredients or packaging.
- Inability to secure pharmacy or payer placement.
- Price erosion caused by multiple approved suppliers.
- Product liability and labeling exposure.
- State-specific substitution restrictions.
A new entrant could generally compete without conducting a large efficacy trial, but it would still need an approved application, compliant manufacturing, validated analytical methods, appropriate labeling, and reliable commercial supply.
What geographic markets are relevant to Nordette-21?
Nordette-21 and equivalent formulations have commercial relevance in markets where combined oral contraceptives are approved and accessible. Product names, strengths, pack sizes, prescription status, reimbursement, and regulatory classifications vary by country.
Geographic value is highest where:
- Oral contraceptive use is established.
- Generic substitution is permitted.
- Supply is concentrated among a small number of manufacturers.
- Public procurement creates predictable volume.
- Long-acting contraceptive access remains limited.
- Local manufacturing or registration provides a distribution advantage.
A global patent strategy is not central to the product. Geographic barriers are more likely to involve local registration, pricing controls, import requirements, pharmacovigilance, and procurement rules.
Key Takeaways
- Nordette-21 is a mature combined oral contraceptive containing levonorgestrel 0.15 mg and ethinyl estradiol 0.03 mg.
- It has no meaningful current clinical-development pipeline.
- Its clinical support comes from established evidence for combined oral contraceptives and postmarketing safety data.
- The conventional formulation is post-exclusivity and faces extensive generic competition.
- Paragraph IV litigation is not a central current risk for the basic 21-tablet product.
- Biosimilar analysis does not apply because Nordette-21 is a small-molecule tablet.
- Patent strength is weak; manufacturing, supply, reimbursement, and distribution determine commercial performance.
- Brand revenue is likely limited, while generic demand remains durable but price-sensitive.
- Product-level revenue projections require manufacturer, country, volume, and net-price data that are not generally reported in public filings.
- The most realistic commercial opportunity is low-cost, reliable generic supply rather than patent-protected differentiation.
FAQs
Is Nordette-21 still available?
Availability varies by country, manufacturer, and distributor. Generic levonorgestrel/ethinyl estradiol products may remain available even where the original Nordette brand is discontinued or difficult to source.
Is Nordette-21 the same as levonorgestrel and ethinyl estradiol?
Nordette-21 refers to a brand regimen containing those active ingredients at 0.15 mg and 0.03 mg, respectively. Generic products with the same strength and approved therapeutic-equivalence status may be substituted subject to applicable law and pharmacy policy.
Does Nordette-21 require a new clinical trial for generic approval?
A generic applicant generally does not need to repeat large contraceptive efficacy trials. It must satisfy the applicable FDA requirements for pharmaceutical quality, equivalence, bioequivalence, labeling, and manufacturing.
Can a company patent a new Nordette-21 package?
Packaging alone usually provides limited exclusivity. A patent may be possible for a genuinely novel packaging system or adherence technology, but it would not necessarily block conventional tablets sold in standard packaging.
Is Nordette-21 safer than newer contraceptives?
Safety depends on the individual patient’s risk factors, contraindications, adherence, and chosen method. No general safety ranking can replace the product label and clinician assessment. Combined oral contraceptives carry estrogen-related thromboembolic and cardiovascular warnings.[1]
References
-
U.S. Food and Drug Administration. (2023). Levonorgestrel and ethinyl estradiol tablets: Prescribing information. FDA-approved labeling.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
-
U.S. National Library of Medicine. (2024). DailyMed: Levonorgestrel and ethinyl estradiol tablet labeling. National Institutes of Health.
-
World Health Organization. (2023). Medical eligibility criteria for contraceptive use (6th ed.). World Health Organization.
